Medicofarma Biotech (WAR:MDB) Cyclically Adjusted Revenue per Share: zł0.56 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:MDB Medicofarma Biotech SA WAR:MDB
34 GF Score
Price zł0.42
GF Value zł0.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medicofarma Biotech Cyclically Adjusted Revenue per Share?

Medicofarma Biotech WAR:MDB -1.42% 34 Cyclically Adjusted Revenue per Share is zł0.56 as of Mar. 2026. GuruFocus rates WAR:MDB with a GF Score™ of 34/100 and a GF Value™ of zł0.05 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Medicofarma Biotech's adjusted revenue per share for the three months ended in Mar. 2026 was zł0.001. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is zł0.56 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Medicofarma Biotech's average Cyclically Adjusted Revenue Growth Rate was -6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Medicofarma Biotech was -3.60% per year. The lowest was -3.60% per year. And the median was -3.60% per year.

As of today (2026-07-16), Medicofarma Biotech's current stock price is zł0.416. Medicofarma Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was zł0.56. Medicofarma Biotech's Cyclically Adjusted PS Ratio of today is 0.74.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medicofarma Biotech was 2.97. The lowest was 0.42. And the median was 1.48.


Medicofarma Biotech  (WAR:MDB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medicofarma Biotech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.416/0.56
=0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medicofarma Biotech was 2.97. The lowest was 0.42. And the median was 1.48.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Medicofarma Biotech Cyclically Adjusted Revenue per Share Related Terms


Medicofarma Biotech Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Medicofarma Biotech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicofarma Biotech Cyclically Adjusted Revenue per Share Chart

Medicofarma Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.72 0.00 0.61 0.00

Medicofarma Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.00 0.00 0.00 0.56

WAR:MDB vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medicofarma Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicofarma Biotech Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicofarma Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medicofarma Biotech's Cyclically Adjusted PS Ratio falls into.


WAR:MDB
34GF Score
Medicofarma Biotech SA WAR:MDB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicofarma Biotech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medicofarma Biotech's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.001/163.0700*163.0700
=0.001

Current CPI (Mar. 2026) = 163.0700.

Medicofarma Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.124 99.552 0.203
201609 0.164 99.064 0.270
201612 0.223 100.366 0.362
201703 0.143 101.018 0.231
201706 0.146 101.180 0.235
201709 0.165 101.343 0.265
201712 0.294 102.564 0.467
201803 0.146 102.564 0.232
201806 0.136 103.378 0.215
201809 0.167 103.378 0.263
201812 0.284 103.785 0.446
201903 0.107 104.274 0.167
201906 0.106 105.983 0.163
201909 0.095 105.983 0.146
201912 0.160 107.123 0.244
202003 0.097 109.076 0.145
202006 0.125 109.402 0.186
202009 0.137 109.320 0.204
202012 0.180 109.565 0.268
202103 0.005 112.658 0.007
202106 0.012 113.960 0.017
202109 0.008 115.588 0.011
202112 0.024 119.088 0.033
202203 0.045 125.031 0.059
202206 0.005 131.705 0.006
202209 0.005 135.531 0.006
202212 0.007 139.113 0.008
202303 0.004 145.950 0.004
202306 0.003 147.009 0.003
202309 0.005 146.113 0.006
202312 0.000 147.741 0.000
202403 0.013 149.044 0.014
202406 0.003 150.997 0.003
202409 0.000 153.439 0.000
202412 0.002 154.660 0.002
202503 0.002 157.021 0.002
202506 0.000 157.509 0.000
202509 0.000 158.000 0.000
202512 0.000 158.320 0.000
202603 0.001 163.070 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of zł0.56 mean?
Medicofarma Biotech (WAR:MDB) has a Cyclically Adjusted Revenue per Share of zł0.56 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medicofarma Biotech and its competitors.
Is Medicofarma Biotech's Cyclically Adjusted Revenue per Share too high?
Medicofarma Biotech's current Cyclically Adjusted Revenue per Share is zł0.56. Overall, Medicofarma Biotech has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medicofarma Biotech's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Medicofarma Biotech's Cyclically Adjusted Revenue per Share of zł0.56 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medicofarma Biotech and its competitors. Medicofarma Biotech's current Cyclically Adjusted Revenue per Share is zł0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicofarma Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicofarma Biotech (WAR:MDB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.05, compared to a current price of zł0.42 — trading 732% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is zł0.56. Medicofarma Biotech's overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Medicofarma Biotech (WAR:MDB), the current Cyclically Adjusted Revenue per Share is zł0.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?

Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued. The current stock price of zł0.42 is trading 732% above its estimated GF Value™ of zł0.05. GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.

Key valuation signals for WAR:MDB:

  • Cyclically Adjusted Revenue per Share: zł0.56
  • GF Value™: zł0.05 vs. price of zł0.42 (732% above fair value)
  • GF Score™: 34/100 with 6 warning signs

No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medicofarma Biotech Business Description

Address ul. Sokołowska 9 lok. U19, Warsaw, POL, 01-142
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
34GF Score

Get the complete analysis for WAR:MDB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.42
Price
zł0.05
GF Value